LOOP-ENERGY/NGVI
17.8.2021 14:02:07 CEST | Business Wire | Press release
Loop Energy (TSX:LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces the placement of the order for the first eFlow™ powered Hydrogen Fuel Cell Systems under a commercial agreement with NGVI, a South Korean-based manufacturer of turn-key compressed natural gas and hydrogen fuel systems for transit and coach bus applications. This announcement is an important milestone for Loop Energy as it signifies accelerating adoption of the eFlow™ fuel cell platform within the transit bus market vertical as well as Loop Energy’s official entry into the highly dynamic zero-emission commercial vehicle market in South Korea.
Under the agreement, Loop Energy will supply NGVI with the latest generation of its hydrogen fuel cell system offering featuring a fully integrated package of fuel cell module, cooling system and DCDC power conditioning equipment. NGVI is well positioned as a supplier within the South Korean bus market, with Seoul Bus company and TCHA Partners having a share of ownership in NGVI.
“With Loop’s state-of-the-art technology and NGVI’s system integration expertise and customer network, we believe we can make hydrogen electric transit a reality in South Korea and beyond,” said Ben Nyland, President and Chief Executive Officer of Loop Energy. “Our fully integrated fuel cell system product line incorporates a lot of the input we collected from the customers, and the performance has been nothing short of outstanding. From the field data rolling in daily from previously announced municipal bus fleet in Nanjing, China, to new customer engagements in Eastern Europe and now in Korea, we are very pleased with the success we had in the transit bus market over the last few months.”
The first hydrogen fuel cell system supplied under the agreement is earmarked for construction of the first testing and homologation vehicles under the agreement signed between NGVI and Ulsan Metropolitan City for supply of hydrogen electric transit buses. Under the first phase of the multi-year agreement, Ulsan is anticipated to invest 2.3 billion KRW (approximately $2.0 million USD) by 2024 in testing and certification of hydrogen bus technologies, supplied by a consortium of partners including NGVI. Ulsan announced a plan in 2018 to replace 40% of the city’s 949 buses with hydrogen-fueled vehicles and establish 60 hydrogen fueling stations by 2030.
After development and demonstration, the buses are expected to expand to fleet used in the capital area where Seoul Bus Company and TCHA Partners own over 1,200 buses. The city says demand will rise as approximately 10 percent of Seoul buses are replaced or decommissioned annually. The number of buses owned by them is expected to be more than 2,000 by 2023, and the demand in the metropolitan area is expected to be more than 200 per year.
“The future of bus transit fleet depends on hydrogen fuel cell technology, and we are extremely pleased to kick off the project with NGVI,” said Hyun Tae Hwang, Head Researcher at Ulsan Technopark that actually leads the project by consignment from Ulsan City. “To make the economics work, fuel efficiency is important to us because it is the largest share of our total operating cost, and we are committed to using the vehicles equipped with most advanced hydrogen fuel cell systems that NGVI can supply.”
“Our major shareholders include some of Korea’s largest bus fleet operators. As a result, we have a unique level of appreciation for the impact vehicle’s cost of ownership has on how quickly South Korea’s bus transit with adopting hydrogen technology,” said David Jung, Chief Executive Officer of NGVI. “We have chosen to partner with Loop Energy because their products combine performance and economics into one value proposition that gives fleet operators exactly what they want.”
About NGVI
NGVI (Natural Gas Vehicles International) is a South-Korea based company specializing in the first compressed natural gas fuel storage and supply system modules. Founded in 2000, NGVI is an IATF 16949 certified company and provides 2,000 modules per year to its customers. In addition to natural gas vehicles, NGVI also assists with the design, development and manufacturing of fuel storage and supply systems for hydrogen vehicles and are planning to extend their services to other areas of transportation, including trains and ships. www.ngvi.co.kr
About Loop Energy Inc.
Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including, light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop’s products feature the Company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow™ was designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com .
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the ability of the Company to execute on its strategy and the factors discussed under “Risk Factors” in the final long-form prospectus of the Company dated February 18, 2021. Loop disclaims any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210817005246/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
